Editas Medicine (EDIT) PT Lowered to $60 at Raymond James
Tweet
Share
E-mailGet Alerts EDIT Hot Sheet
Price: $5.61 -4.1%
Rating Summary:
11 Buy, 10 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 13 | New: 18
Rating Summary:
11 Buy, 10 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 13 | New: 18
Join SI Premium – FREE
Raymond James analyst Steven Seedhouse lowered the price target on Editas Medicine (NASDAQ: EDIT) to $60.00 (from $65.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Sage Therapeutics (SAGE) PT Lowered to $17 at Oppenheimer
- Morgan Stanley Upgrades Macquarie Group Ltd. (MQG:AU) (MQBKY) to Overweight
- First Quantum Minerals (FM:CN) (FQVLF) PT Raised to Cdn$15 at CIBC
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
